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BASIC SCIENCES
Antiplatelet Effect of Carbon Monoxide Is 
Mediated by NAD+ and ATP Depletion
Patrycja Kaczara , Barbara Sitek, Kamil Przyborowski , Anna Kurpinska , Kamil Kus, Marta Stojak , Stefan Chlopicki
OBJECTIVES: Carbon monoxide (CO) produced by haem oxygenases or released by CO-releasing molecules (CORM) affords 
antiplatelet effects, but the mechanism involved has not been defined. Here, we tested the hypothesis that CO–induced 
inhibition of human platelet aggregation is mediated by modulation of platelet bioenergetics.
APPROACH AND RESULTS: To analyze the effects of CORM-A1 on human platelet aggregation and bioenergetics, a light transmission 
aggregometry, Seahorse XFe technique and liquid chromatography tandem-mass spectrometry–based metabolomics were 
used. CORM-A1–induced inhibition of platelet aggregation was accompanied by the inhibition of mitochondrial respiration and 
glycolysis. Interestingly, specific inhibitors of these processes applied individually, in contrast to combined treatment, did not 
inhibit platelet aggregation considerably. A CORM-A1–induced delay of tricarboxylic acid cycle was associated with oxidized 
nicotinamide adenine dinucleotide (NAD+) depletion, compatible with the inhibition of oxidative phosphorylation. CORM-A1 
provoked an increase in concentrations of proximal (before GAPDH [glyceraldehyde 3-phosphate dehydrogenase]), but 
not distal glycolysis metabolites, suggesting that CO delayed glycolysis at the level of NAD+–dependent GAPDH; however, 
GAPDH activity was directly not inhibited. In the presence of exogenous pyruvate, CORM-A1–induced inhibition of platelet 
aggregation and glycolysis were lost, but were restored by the inhibition of lactate dehydrogenase, involved in cytosolic NAD+ 
regeneration, pointing out to the key role of NAD+ depletion in the inhibition of platelet bioenergetics by CORM-A1.
CONCLUSIONS: The antiplatelet effect of CO is mediated by inhibition of mitochondrial respiration—attributed to the inhibition 
of cytochrome c oxidase, and inhibition of glycolysis—ascribed to cytosolic NAD+ depletion.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: carbon monoxide ◼ glycolysis ◼ oxidative phosphorylation ◼ platelet aggregation ◼ tandem-mass spectrometry
Carbon monoxide (CO) delivered to an organism through inhalation is lethally toxic. Hence, for a long time, CO has been referred to as a silent killer. 
However, CO produced endogenously during haem 
degradation by haem oxygenase enzymes is an impor-
tant endogenous signalling molecule implied in cellular 
responses to various stimuli.1 In turn, CO supplied in rela-
tively low quantities by CO-releasing molecules (CORMs) 
affords cytoprotective and anti-inflammatory effects.1,2
See accompanying editorial on page 2344
Numerous reports provide evidence that CO, due to its 
antiplatelet and antithrombotic action, plays an important role 
in maintaining vascular homeostasis in vivo. For example, it 
was demonstrated that HO-1 (haem oxygenase 1)-derived 
CO protects against hepatic ischemia-reperfusion injury 
through the inhibition of platelet adhesion to the sinusoids.3 
Moreover, HO-1-deficiency induces an acceleration of 
arterial thrombosis, which occurs through various mecha-
nisms (including platelet activation), while CO inhalation4 or 
CO delivery by CORM-25 can rescue from prothrombotic 
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importance of HO-1-derived CO in the regulation of vascu-
lar thromboresistance and suggest that CORMs may repre-
sent a novel class of antiplatelet agents. Indeed, CORM-A1, 
a prototypic CORM slowly releasing CO,6 was shown to 
afford antiplatelet and antithrombotic activities in vivo with-
out any hypotensive effect, while CORM-3, which releases 
CO instantly, displayed both antithrombotic and hypoten-
sive effects.7 Recently, various novel CORMs with tuneable 
CO-releasing properties have been synthetized, all of which 
were shown to display antiplatelet activity similar or even 
slightly more pronounced than CORM-A1,8 confirming the 
significant antiplatelet effects of CORMs.
Despite the firm evidence on the antiplatelet effects 
of CO in in vivo and in vitro studies, the mechanisms 
involved have not been elucidated so far. Even though 
high concentrations of gaseous CO act in platelets via 
sGC (soluble guanyl cyclase),9,10 the antiplatelet effect of 
CORM-3, in contrast to NO-donors, was not mediated by 
the activation of sGC.11,12 Recently, the involvement of gly-
coprotein-mediated HS1 phosphorylation was suggested 
to be involved in CORM-2-induced suppression of plate-
let activation by LPS (lipopolysaccharide).13 However, this 
mechanism does not explain the antiplatelet effect of CO 
reported for platelet aggregation induced by classical 
platelet agonists such as collagen or thrombin,11,12 which 
entail a mechanistically distinct intraplatelet pathways as 
compared with LPS-induced platelet activation.14
Platelet aggregation is an energy-demanding pro-
cess.15,16 In resting or activated states, platelets draw 
energy from oxidative phosphorylation and glycolysis.17–19 
However, besides a couple of works describing altered 
bioenergetics of platelets derived from patients with 
sickle cell disease,20 asthma,21 sepsis,22 Parkinson dis-
ease23 or diabetes mellitus,24 still little is known about the 
role of metabolism in the regulation of platelets’ function. 
A number of reports, including ours, have demonstrated 
that CO modulates cellular bioenergetics in various cells 
types,25–30 including endothelial cells.31–33
Given the fact that platelet aggregation is an energy-
demanding process, we hypothesized that CO may mod-
ulate platelet activity through the modulation of platelet 
bioenergetics involving oxidative phosphorylation and 
glycolysis. In the present work, we have characterized the 
bioenergetics of platelets in resting and activated states, 
and analyzed the effects of CORM-A1, on mitochondrial 
respiration, glycolysis, and metabolome in platelets. We 
have chosen CORM-A1 because of its well documented 
antiplatelet action in in vitro and in vivo models.7,12 Here, we 
propose that the mechanism of antiplatelet effect of CO 
involves the inhibition of 2 major ATP-generating pathways 
in platelets—mitochondrial respiration and glycolysis, by the 
inhibition of cytochrome c oxidase and cytosolic nicotin-
amide adenine dinucleotide (NAD+) depletion, respectively.
METHODS
The authors declare that all supporting data are available within 
the article in the Data Supplement.
Isolation of Human Platelets
Venous blood was obtained from male volunteers at the 
University Hospital Blood Bank Centre. Volunteer donors had 
not taken any medicines for the preceding 2 weeks. Informed 
consent was given by a volunteer before the blood withdrawal 
and study conformed to the principles outlined in the World 
Medical Association Declaration of Helsinki. Blood obtained 
from at least 3 donors per one independent experiment was 




CORM carbon monoxide-releasing molecule
DHAP dihydroxyacetone phosphate
ECAR extracellular acidification rate
GA3P glyceraldehyde 3-phosphate




NAD+ nicotinamide adenine dinucleotide
OCR oxygen consumption rate
PFK-1 phosphofructokinase 1
PPP pentose phosphate pathway
SDH succinate dehydrogenase
sGC soluble guanyl cyclase
TCA tricarboxylic acid cycle
WP washed platelets
Highlights
• Carbon monoxide was identified to inhibit platelet 
aggregation, but the mechanism involved has not 
been defined.
• We observed that antiplatelet effect of carbon 
monoxide is accompanied by inhibition of mito-
chondrial respiration and inhibition of glycolysis at 
the level of GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase).
• In the presence of exogenous pyruvate inhibitory 
effects of carbon monoxide on platelet aggregation 
and glycolysis were lost, but restored after inhibition 
of cytosolic NAD+ regeneration, suggesting a key 
role of NAD+ depletion in the observed effects.
• Antiplatelet effect of carbon monoxide is mediated 
by inhibition of both ATP-generation processes, 
mitochondrial respiration at the level of cytochrome 
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collected into vials containing sodium citrate (3.2%, 9:1v/v) 
as an anticoagulant agent. Blood was centrifuged (260g, 15 
minutes) followed by a centrifugation/washing cycle using 
prostacyclin-containing PBS (PBS containing albumin [1 g/L] 
and glucose [1 g/L]), according to the previously described 
method.34 Washed platelets (WP) were finally suspended in 
assay medium (Seahorse XF Base Medium Minimal DMEM 
supplemented with glucose [1 g/L] and glutamine [2 mmol/L], 
pH 7.4) at a density of 2×105 platelets/µL, unless otherwise 
stated. Contamination of neutrophils in WP was <1/106 
platelets.
Platelet Aggregation Assay in Humans
Aggregation of blood platelets was assessed in WP using a 
dual channel aggregometer (CHRONO-LOG) according to 
the method previously described by Born.35 WP (500 µL) were 
equilibrated for 2 minutes at 37°C with a continuous stirring 
at 800 rpm and then stimulated with collagen or thrombin to 
cause aggregation. At the beginning of each experiment, con-
centrations of thrombin (in the range of 0.1–0.5 U/mL) that 
induced sub-maximum aggregation response were determined. 
CORM-A1, metabolic inhibitors, and other tested compounds 
were added 2 minutes before stimulation of platelets with colla-
gen or thrombin. Transmittance was read within 6 minutes after 
stimulation of platelets with an agonist. The concentrations of 
CO released from CORM-A1 were measured with myoglobin 
assay (Figure I in the Data Supplement), as described previ-
ously36 with minor changes (Materials in the Data Supplement).
Analysis of Cellular Bioenergetics Using 
Extracellular Flux Technology
To measure mitochondrial function and glycolysis in isolated 
human platelets, a Seahorse XFe96 Analyzer was used (the 
details are in Materials in the Data Supplement). Briefly, freshly iso-
lated platelets suspended in assay medium were introduced into 
the Seahorse XFe96-well plates (10×106 of platelets per well) 
followed by centrifugation (5 minutes, 700g) and incubation with 
bicarbonate-free low buffered assay medium (1 hour, 37°C) in air 
without CO2 before the beginning of the assay. Changes in oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) 
were assessed over time by sequential injections of reagents in 
ports A, B, C, and D. Concentrations of oligomycin, FCCP (car-
bonyl cyanide 4-[trifluoromethoxy]phenylhydrazone), rotenone, 
and antimycin A were optimized (data not shown). Mitochondrial 
stress test enabled determination of the following key parameters 
of mitochondrial function: acute response, proton leak, maximal 
respiration, spare respiratory capacity, ATP production, and non-
mitochondrial oxygen consumption (calculated as described in 
Materials in the Data Supplement). Additionally, we calculated 
acute response and oligomycin-induced changes in ECAR. We 
analyzed the effects of CORM-A1 on thrombin-induced changes 
in OCR (Δ [Thr-A1]
mt. respiration) and in ECAR (Δ [Thr-A1]glycolysis), cal-
culated based on the differences in OCR and ECAR before and 
after thrombin injection. Based on the experiments with oligomy-
cin, we analyzed the ability of platelets pretreated with CORM-A1 
and thrombin to further maximize their glycolysis in response to 
oligomycin, reflecting a spare glycolytic capacity (Δ [O-Thr]), while 
based on the experiments with FCCP/pyruvate, we analyzed the 
ability of platelets pretreated with CORM-A1 and thrombin to fur-
ther maximize their mitochondrial respiration in response to FCCP, 
reflecting a spare respiratory capacity (Δ [FCCP-Thr]).
Lactate Measurements
Measurements of lactate were performed by the enzymatic 
photometric methods using an automatic Pentra 400 (Horiba, 
Japan) biochemical analyzer according to the manufacturer’s 
instructions. Samples were suspended in assay buffer at a den-
sity of 3×104 platelets/µL and treated with tested compounds 
for 8 minutes at 37°C or preincubated with tested compounds 
for 2 minutes and then activated with thrombin for 6 minutes 
at 37°C, followed by centrifugation (1000g, 10 minutes) and 
measurement of the concentration of lactate in supernatant.
Analysis of Intraplatelet Metabolites
Detection of intraplatelet metabolites was performed accord-
ing to the protocol described previously,33,37 with minor changes. 
Briefly, WP (suspended in PBS containing 1 g/L glucose and 
2 mmol/L glutamine, in a number of 500×106 per 0.5 mL per 
sample) were untreated or preincubated for 2 minutes with 300 
µmol/L CORM-A1, followed by the addition of thrombin (0.1 U/
mL) and further incubation for 6 minutes. The metabolism was then 
quenched by the addition of 0.5 mL of extraction solution (aceto-
nitrile: methanol: water, 5:2:3, v/v/v) cooled to −80°C. Metabolites 
were extracted by sonication for 15 minutes on ice, centrifuged 
(15 000g, 15 minutes, 4°C) and lyophilized. Before analysis, the 
samples were reconstituted in water, injected into a liquid chro-
matography column, and analyzed on a QTRAP 5500 (Sciex, 
Framingham, MA) coupled with UFLC (ultra-fast liquid chromatog-
raphy) Nexera (Shimadzu, Kyoto, Japan). Chromatography separa-
tion was achieved on an Acquity UPLC BEH C18 1.7 µm 3.0×100 
mm analytical column (Waters, Milford, MA). Samples were ana-
lyzed twice in positive and negative ionization MRM (multiple reac-
tion monitoring) mode. For the analysis in positive ionization using 
acetonitrile, 100 mmol/L ammonium formate (pH 5.0) 95:5 v/v 
and 5 mmol/L ammonium formate (pH 5.0) were used as a mobile 
phase using gradient elution. The total run time was 8 and 10 min-
utes for negative and positive ionization modes, respectively.
Analysis of GAPDH and PFK-1 Activities
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) activ-
ity was analyzed in samples of WP (suspended in PBS con-
taining 1 g/L glucose and 2 mmol/L glutamine, in a number 
of 300×106 per 0.5 mL per sample) untreated or incubated 
for 8 minutes with CORM-A1, processed as described by 
Schmidt and Dringen38 and measured according to the proto-
col described by Bisswanger.39 PFK-1 (phosphofructokinase 1) 
activity was analyzed followed by incubation of WP (500×106 
per 0.5 mL per sample) with CORM-A1 for 8 minutes or 30 
minutes, according to the protocol described previously.40,41 
Details are described in Materials in the Data Supplement.
Analysis of Metabolic ATP Concentration
Measurements were performed in samples treated for 8 minutes 
with tested compounds, in the presence of apyrase (1 U/mL) 
using ATPlite 1step Luminescence Assay System (PerkinElmer).
Statistical Analysis
Statistical analysis was performed using ORIGINPRO 9.1 soft-
ware (OriginLab Corporation, Northampton, MA) or Graphpad 
Prism software (GraphPad Software, La Jolla, CA). Results 
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have been analyzed for normality, and 1-way ANOVA test was 
performed with Benferroni test; with P values being provided in 
the legends (*P<0.05, #P<0.01, $P<0.001, and &P<0.0001).
RESULTS
Effects of CORM-A1 on Mitochondrial 
Respiration and Glycolysis in Resting Platelets
In resting human WP, CORM-A1 induced a concentra-
tion-dependent decrease in OCR and biphasic changes 
in ECAR as analyzed by the Seahorse XFe technique 
(Figure 1). A slight inhibitory effect of CORM-A1 on 
mitochondrial respiration (Figure 1A) was already visible 
at the concentrations of 10 and 30 µmol/L, with stronger 
effects reaching ≈50% to 60% of basal OCR inhibition at 
concentrations of 100 to 300 µmol/L. The mitochondrial 
stress test (Figure 1C) revealed that CORM-A1 induced 
a decrease in ATP-linked respiration, maximal respira-
tion, and spare respiratory capacity, which all may have 
resulted from the inhibition of cytochrome c oxidase by 
CO. CORM-A1 induced a slight increase in proton leak, 
but did not affect nonmitochondrial oxygen consumption. 
CORM-A1 decreased also intraplatelet ATP concentra-
tion as assessed by biochemical assay (Figure 1D).
Biphasic effects of CORM-A1 on glycolysis com-
prised a slight increase in ECAR for the lower concentra-
tions (10–100 µmol/L) and a decrease in ECAR for the 
higher concentrations (200 and 300 µmol/L) of CORM-
A1 (Figure 1B). To confirm that all the described effects 
Figure 1. Effects of CORM-A1 on mitochondrial respiration and glycolysis in resting human platelets as monitored by Seahorse 
XFe96 Analyzer.
Oxygen consumption rate (OCR; A) and extracellular acidification rate (ECAR; B) measurements of human washed platelets (WP) treated with 
PBS (control), CORM-A1 (A1; 10–300 μmol/L) or inactive CORM-A1 (iA1; 300 μmol/L) followed by sequential addition of oligomycin (1 μg/
mL), FCCP (carbonyl cyanide 4-[trifluoromethoxy]phenylhydrazone)/pyruvate (0.3 μmol/L/1 mmol/L) and rotenone/antimycin A (0.5/0.5 μmol/L). 
Bioenergetic parameters of mitochondrial respiration and glycolysis (C) were calculated as described in Materials in the Data Supplement. Data 
represent the means±SD of 2 independent experiments; n=4–6 replicates in each experiment. D, Intracellular ATP concentration measured in 
platelets treated with PBS or CORM-A1 together with apyrase (1 U/mL) to remove released extracellular ATP. Data represent the means±SD 
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of CORM-A1 were induced by CO, inactive CORM-A1 
was used, which neither induced changes in mitochon-
drial respiration nor in glycolysis. The levels of LDH (lac-
tate dehydrogenase) released into the assay medium 
after CORM-A1 or lysis buffer treatment confirmed 
that CORM-A1 in the concentration range of 10 to 300 
µmol/L did not affect viability of platelets (Figure II in the 
Data Supplement).
Effects of CORM-A1 on Mitochondrial 
Respiration and Glycolysis in Activated 
Platelets
To characterize the effects of CO on bioenergetics 
of activated platelets, mitochondrial stress test was 
performed in WP, which were pretreated with CORM-
A1 and then activated with thrombin (0.1 U/mL). 
Thrombin induced a slight increase (by 11±2.2%) 
in OCR, which was further increased by FCCP (Fig-
ure 2A and 2E). In contrast to the mild activation of 
OCR, thrombin induced a substantial increase (by 
116±0.7%) in ECAR, which was further increased 
by oligomycin (Figure 2D and 2E). In the presence 
of CORM-A1, the thrombin-induced increase in OCR 
was diminished, in particular for 100 or 300 µmol/L 
CORM-A1 as compared with control platelets (Δ 
[Thr-A1] in Figure 2E). When mitochondrial respiration 
was further activated with FCCP, CORM-A1 in a con-
centration-dependent manner in a wide range of con-
centrations (10–300 µmol/L) diminished the increase 
Figure 2. Effects of CORM-A1 on mitochondrial respiration and glycolysis in parallel to aggregation in activated platelets.
Oxygen consumption rate (OCR; A and C) and extracellular acidification rate (ECAR; B and D) measurements of human washed platelets 
(WP) treated with PBS (control) or CORM-A1 (A1; 10–300 μmol/L) followed by the addition of thrombin (0.1 U/mL) and further sequential 
addition of FCCP (carbonyl cyanide 4-[trifluoromethoxy]phenylhydrazone)/pyruvate (0.3 μmol/L/1 mmol/L) and rotenone/antymycin A (R/A; 
0.5/0.5 μmol/L; A and B) or oligomycin (1 μg/mL) and R/A (C and D). Bioenergetic parameters of mitochondrial respiration and glycolysis (E) 
were calculated as described in the Data Supplement. Data represent the means±SD of 3 independent experiments; n=4–8 replicates in each 
experiment. F, Concentration of lactate extruded from platelets (WP) treated with CORM-A1 (0, 100, 300, 1000 μmol/L; CONT) or CORM-A1 
and thrombin (0.1 U/mL; Thr); data represent the means±SD of 4 independent experiments; n=2 replicates in each experiment. G, Aggregation 
of platelets (WP) treated with CORM-A1 (10, 30, 100, 300 μmol/L) and activated with thrombin (0.5 U/mL) as compared with control; data 
represent the means±SD of 4 independent experiments; n=2 replicates in each experiment. *P<0.05, #P<0.01, $P<0.001, &P<0.0001 as 
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in OCR (Δ [FCCP-A1]). The effects of CORM-A1 on 
thrombin-activated glycolysis were more remarkable 
than those on thrombin-induced increase in OCR, due 
to stronger activation of glycolysis by thrombin. In the 
presence of 100 to 300 µmol/L CORM-A1, thrombin-
activated glycolysis was substantially diminished. Only 
a slight increase in ECAR after thrombin (by around 
30%) was observed for 100 µmol/L CORM-A1 (Δ 
[Thr-A1] in Figure 2), whereas 300 µmol/L CORM-A1 
inhibited glycolysis so strongly that thrombin-induced 
increase in ECAR was abrogated (Δ [Thr-A1] in Fig-
ure 2E). CORM-A1 diminished also oligomycin-induced 
increase in glycolysis (Δ [O-A1]) in a concentration-
dependent manner (10–300 µmol/L). To confirm that 
the observed changes in ECAR resulted from the 
changes in glycolytic flux, lactate extrusion by plate-
lets was measured after thrombin stimulation with or 
without CORM-A1 (Figure 2F). Thrombin (0.1 U/mL) 
increased lactate release, whereas CORM-A1 in a 
concentration-dependent manner (100–1000 µmol/L) 
decreased lactate concentration in supernatant of rest-
ing or thrombin-stimulated platelets (Figure 2F).
The comparison of CORM-A1 effects on platelet bio-
energetics and aggregation revealed that concentrations 
of CORM-A1, which afforded nearly complete inhibition 
of platelet aggregation (100–300 µmol/L, Figure 2G), 
also led to simultaneous and complete inhibition of gly-
colysis and mitochondrial respiration (100–300 µmol/L, 
Figure 2A through 2E). Bioenergetics of platelets 
treated with 10 or 30 µmol/L CORM-A1 was impaired 
to a lesser degree, what was associated with a weaker 
antiplatelet effect. Inactive CORM-A1 (300 µmol/L) did 
not affect platelet aggregation (99.8±2.61% of control, 
n=5) confirming the involvement of CO in CORM-A1–in-
duced effects. Altogether, the concentration-dependent 
antiaggregatory effects of CORM-A1 were mirrored 
by the concentration-dependent inhibition of platelet 
bioenergetics.
Effects of Inhibitors of Mitochondrial 
Respiration and Glycolysis on Platelet 
Bioenergetics and Platelet Aggregation-
Metabolic Plasticity of Platelets
To characterize the reliance of platelets on mitochondrial 
respiration versus glycolysis, the effects of oligomycin 
(inhibitor of ATP synthase), rotenone (inhibitor of com-
plex I), antimycin A (inhibitor of complex III), UK-5099 
(inhibitor of mitochondrial pyruvate carrier), 2-deoxy-D-
glucose (2DG; competitive glycolytic inhibitor), and 3PO 
(inhibitor of PFKFB3 [6-phosphofructo-2-kinase/fruc-
tose-2,6-bisphosphatase 3]) on OCR, ECAR, and plate-
let aggregation were investigated.
2DG profoundly inhibited glycolysis, whereas it 
barely affected mitochondrial respiration (Figure 3A 
and 3B). Only at the highest concentration of 100 
mmol/L, 2DG significantly reduced OCR to 95±0.6% 
of basal (P<0.05). 3PO, another inhibitor of glycoly-
sis, slightly reduced ECAR; however, even though the 
effect was statistically significant, it was not concen-
tration dependent and was associated with concomi-
tant reduction in OCR. In turn, oligomycin at 0.5 to 1 
µg/mL reduced almost completely OCR, which was 
accompanied by a substantial increase in ECAR. Anti-
mycin A and rotenone almost completely reduced OCR 
and highly increased ECAR, whereas UK-5099 slightly 
reduced OCR and increased ECAR. Notably, the com-
plete inhibition of oxidative phosphorylation by oligo-
mycin, antimycin A, or rotenone was compensated by 
almost a 3-fold increase in ECAR.
As shown in Figure 3C, those inhibitors which reduced 
exclusively mitochondrial respiration (oligomycin, antimy-
cin A, rotenone, UK-5099) did not substantially inhibit 
platelet aggregation (less than by 10%). 2DG reduced 
platelet aggregation to 80% of control; however, at this 
concentration, 2DG also slightly reduced OCR. Among 
metabolic inhibitors, the most effective was 3PO, which 
at 30 µmol/L concentration reduced platelet aggrega-
tion to 68% of control (Figure 3C). However, as dem-
onstrated in Figure 3A and 3B, 3PO reduced not only 
ECAR, but also OCR.
Effects of Simultaneous Inhibition of 
Mitochondrial Respiration and Glycolysis on 
Platelet Aggregation
Figure 3D demonstrates the bioenergetics of WP after 
addition of oligomycin and 2DG individually or in com-
bination. Oligomycin at a concentration of 0.5 µg/mL, 
which in the absence of 2DG even slightly increased 
metabolic activity (OCR decreased to 20±4.5% of basal, 
but ECAR increased up to 221±20.8% of basal), in com-
bination with 2DG, caused a profound inhibition of plate-
let bioenergetics that resulted in significant inhibition 
of platelet aggregation (Figure 3E). Indeed, oligomycin 
alone (even at a concentration of 10 µg/mL) inhibited 
platelet aggregation by only 8% (Figure 3E), 2DG alone 
(up to 100 mmol/L) by 21 %. Each of them alone only 
slightly decreased intraplatelet ATP concentration. How-
ever, combination of 2DG and oligomycin (10 µg/mL) 
induced a substantial fall in intraplatelet ATP concentra-
tion (Figure 3F) explaining a profound inhibition of plate-
let aggregation under combined 2DG and oligomycin 
treatment (Figure 3E).
Effect of CORM-A1 on Metabolic Pathways in 
Platelets—Metabolomic Analysis
To explore the effects of CORM-A1 on platelet bioener-
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glycolysis metabolites by targeted metabolomic analysis 
in platelets pretreated with CORM-A1 and stimulated 
with thrombin. As presented in Figure 4, the concen-
trations of TCA cycle metabolites in platelets were not 
substantially changed at sixth minute after thrombin acti-
vation, whereas in the presence of CORM-A1, they were 
reduced (fumarate by 40% and malate by over 50%). 
Moreover, the CORM-A1–induced changes in TCA 
metabolites levels were accompanied by a reduction 
in NAD+ and an increase in NADH concentrations that 
is in agreement with inhibitory effects of CO on mito-
chondrial respiration in platelets. Interestingly, a sum of 
reduced and oxidized NAD (NADH together with NAD+) 
was significantly decreased, whereas a ratio of NADH/
NAD+ was only slightly (nonsignificantly) increased after 
CORM-A1. In turn, glycolytic metabolites measured at 
sixth minute after thrombin stimulation were also not 
changed significantly, whereas CORM-A1 induced a 
massive increase in concentrations of proximal glyco-
lytic metabolites. The concentration of hexose-6-P was 
increased 2-fold, while fructose-1,6-bis-phosphate and 
triose-phosphate (dihydroxyacetone phosphate [DHAP] 
and glyceraldehyde 3-phosphate [GA3P]) levels were 
>10-fold higher comparing to control platelets not 
treated with CORM-A1. Surprisingly, CORM-A1 did not 
induce changes in the concentrations of distal glycolytic 
Figure 3. Effects of single or combined inhibition of mitochondrial respiration and glycolysis by metabolic inhibitors on platelet 
aggregation.
Oxygen consumption rate (OCR; A) and extracellular acidification rate (ECAR; B) measurements of human washed platelets (WP) untreated 
(CONT) or treated with DMSO (as a vehicle), 2-deoxy-D-glucose (2DG), 3PO (3-[3-pyridinyl]-1-[4-pyridinyl]-2E-propen-1-one), oligomycin (OLIG), 
antimycin A (AA), rotenone (ROT) or UK-5099, presented as % of basal 20 minutes after addition of the reagents. Data represent the means±SD of 
3 independent experiments; n=4–8 replicates in each experiment. C, Aggregation of platelets (WP) untreated (CONT) or treated with 2DG, 3PO, 
oligomycin, antimycin A, rotenone or UK-5099, and activated with thrombin (0.5 U/mL), presented as % of control; data represent the means±SD of 
4 independent experiments, n=1–3 replicates in each experiment. D, OCR and ECAR measurements of WP treated with combined inhibitors: 2DG 
and oligomycin presented as % of basal 20 min after addition of the reagents. E, Aggregation of WP treated with combined inhibitors: 2DG and 
oligomycin (10 μg/mL) activated with thrombin (0.5 U/mL); presented as % of control. Data represent the means±SD of 3 independent experiments. 
F, Intraplatelet ATP concentration in WP treated with combined inhibitors: 2DG and oligomycin, measured in the presence of apyrase (1 U/mL). 
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metabolites (3-phospho-glicerate, phosphoenolpyruvate, 
and pyruvate; Figure 5). Noteworthy, the altered balance 
between proximal and distal glycolytic metabolites was 
associated with an increased diversion of glucose into 
pentose phosphate pathway (PPP). Indeed, CORM-A1 
induced an increase in concentrations of PPP metabo-
lites (ribose-5-phosphate, sedoheptulose-7-phosphate, 
and erythrose-4-phosphate) that was not associated 
with an increase in NADPH or NADPH/NADP+ ratio 
(Figure 5).
These results, showing an activation of PPP and 
accumulation of proximal glycolytic metabolites, strongly 
suggest that the inhibition of glycolysis by CORM-
A1 was targeted at the level of GAPDH. However, an 
activity of GAPDH in platelet was not inhibited directly 
by CORM-A1 (Figure 5). Similarly, another rate-limiting 
step of proximal glycolysis—the reaction catalyzed by 
PFK-1—was not modulated by CORM-A1, as evidence 
by the lack of effects of 8-minute long incubation with 
CORM-A1 on PFK-1 activity in platelets (data not 
shown). Only prolonged 30-minute incubation allowed 
to observe an inhibition of this enzyme (Figure IA), that 
was, however, not relevant to the inhibition of glycolysis 
by short-term exposure of CORM-A1. Another possible 
explanation for the inhibition of glycolysis at the level of 
GAPDH by CORM-A1 might have been linked directly to 
NAD+ depletion (Figure 4).
Reversal of Effects of Pyruvate on CORM-A1–
Induced Inhibition of Platelet Aggregation and 
Glycolysis; Role of LDH and NAD+ Regeneration
As LDH is a major enzymatic source for NAD+ regenera-
tion, we tested whether pyruvate could reverse antiplate-
let effects of CORM-A1. As shown in Figure 6A, in the 
presence of pyruvate (1 mmol/L) the inhibitory effect of 
CORM-A1 on platelet aggregation was lost (Figure 6A) 
with concomitant increase in lactate release (Figure 6B) 
Figure 4. Effects of CORM-A1 
on tricarboxylic acid cycle (TCA) 
metabolites and nicotinamide 
adenine dinucleotide (NAD+) content 
in platelets.
Human washed platelets (WP) suspended 
in PBS containing glucose (1 g/L) and 
glutamine (2 mmol/L) were untreated (8 
min; C), treated with CORM-A1 (300 
μmol/L; 8 min; A1), treated with thrombin 
(0.1 U/mL; T) or treated with CORM-A1 
and thrombin (2+6 min; A1/T). Data show 
amounts of metabolic by-products in TCA 
cycle. Data are presented as means±SD 
(nmoL/109 platelets) of 4 independent 
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and ECAR (Figure 6C), in contrast to the absence of 
pyruvate (Figure 1). These data confirmed a high activity 
of LDH, catalyzing the conversion of exogenous pyruvate 
into lactate, accompanied by the regeneration of cyto-
solic NAD+ from NADH. Importantly, in the presence of 1 
mmol/L pyruvate, the accumulation of proximal glycolysis 
intermediates (fructose-1,6-bis-phosphate and DHAP/
GA3P; Figure 6D through 6F) was abrogated, and gly-
colysis flux was efficient again, as also evidenced by 
the lack of accumulation of PPP intermediates (ribose-
5-phosphate, sedoheptulose-7-phosphate, erythrose-
4-phosphate; Figure 6H through 6K). These results 
suggest that pyruvate–induced LDH–dependent regen-
eration of NAD+ reversed glycolysis inhibition at the level 
Figure 5. Effects of CORM-A1 on glycolysis and pentose phosphate pathway (PPP) metabolites in platelets.
Human washed platelets (WP) suspended in PBS containing glucose (1 g/L) and glutamine (2 mmol/L) were untreated (8 min; C), treated 
with CORM-A1 (300 μmol/L; 8 min; A1), treated with thrombin (0.1 U/mL; T) or treated with CORM-A1 and thrombin (2+6 min; A1/T). Data 
show amounts of metabolic by-products in glycolysis and PPP. Data are presented as means±SD (nmoL/109 platelets) of 4 independent 
experiments. DHAP indicates dihydroxyacetone phosphate; F-1,6-BP, fructose-1,6-bis-phosphate; GA3P, glyceraldehyde 3-phosphate; PEP, 
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of GAPDH. Furthermore, these results demonstrate that 
antiaggregatory effect of CORM-A1 was dependent on 
NAD+ availability, which was modulated by LDH activity. 
To substantiate the finding on the role of LDH and pyru-
vate-dependent regeneration of NAD+ in the reversal of 
the CORM-A1–induced effects, we demonstrated that 
in the presence of GSK2837808A (LDH inhibitor; 5 
µmol/L) the effect of pyruvate (100 µmol/L) was lost, 
and 300 µmol/L CORM-A1 inhibited platelet aggrega-
tion again (Figure 6P). Noteworthy, GSK2837808A in 
Figure 6. Effects of pyruvate on antiplatelet activity of CORM-A1 in platelets.
Human washed platelets (WP) were suspended in assay medium (DMEM) supplemented with glucose (1 g/L) and glutamine (2 mmol/L) 
with or without pyruvate (1 mmol/L). A, Aggregation of WP treated with CORM-A1 (300 μmol/L) and activated with thrombin (0.1 U/mL) as 
compared with control; data represent the means±SD of 4 independent experiments; n=1–2 replicates in each experiment. B, Concentration 
of lactate extruded from platelets (WP) treated with CORM-A1 (0, 100, 300, 1000 μmol/L); data represent the means±SD of 3 independent 
experiments. C, Extracellular acidification rate (ECAR) measurements of WP treated with PBS (control) or CORM-A1 (A1; 100, 300, 1000 
μmol/L) in DMEM supplemented with glucose (1 g/L), glutamine (2 mmol/L), and pyruvate (1 mmol/L); Seahorse XFe96 Analyzer. Data 
represent means±SD from a representative experiment, n=3–6 technical replicates. D–O, Human WP suspended in PBS containing glucose 
(1 g/L) and glutamine (2 mmol/L) without (C, A1) or with pyruvate (1 mmol/L; P, A1/P) were untreated or treated with CORM-A1 (300 μmol/L), 
followed by activation with thrombin (0.1 U/mL; 6 min); data demonstrate concentrations of selected metabolic by-products of glycolysis, 
PPP or mitochondrial respiration are presented as means±SD (nmol/109 platelets) of 3 independent experiments, n=2 replicates in each 
experiment. P, Aggregation of WP treated with pyruvate (100 μmol/L), CORM-A1 (300 μmol/L) and GSK2837808A (GSK; 5 μmol/L). Q, 
Aggregation of WP control or preincubated with dimethyl malonate (DMM; 15 min) followed by treatment with antimycin A (AA; 10 μmol/L) 
and GSK2837808A (GSK; 3 μmol/L). Data represent the means±SD of 4 independent experiments; n=1–3 replicates in each experiment. 
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the absence of pyruvate, when added alone, only slightly 
reduced platelet aggregation, but in combination with 
CORM-A1 displayed significant antiplatelet effect (Fig-
ure 6P). Furthermore, combination of GSK2837808A 
with antimycin A resulted in a clear-cut antiaggregatory 
effect, even though neither of them given alone affected 
platelet aggregation (Figure 6Q). To test a putative func-
tional role of NAD+ derived from malate-aspartate shuttle 
in platelets, we combined CORM-A1 or antimycin A with 
aminooxyacetic acid (an inhibitor of malate-aspartate 
shuttle), but in contrast to the combination of CORM-
A1 with GSK2837808A, we did not observe enhance-
ment of antiaggregatory effects of CORM-A1 (data 
not shown). Dimethyl malonate, which intracellularly is 
converted to malonate (an inhibitor of SDH [succinate 
dehydrogenase]), did not show significant antiaggrega-
tory effects alone or in various combinations, excluding 
a possible role of SDH and malate-aspartate shuttle to 
regenerate NAD+ in CORM-A1–treated platelets.
To further confirm, the key role of cytosolic NAD+ 
depletion in the antiplatelet effects of CORM-A1, we 
examined the effects of CORM-A1 on aggregation 
of platelets pretreated with 78c (0.3–20 µmol/L), an 
inhibitor of CD38—one of the major NAD+ consum-
ing enzymes. The inhibition of CD38 by 1 µmol/L 78c 
blunted antiaggregatory effect of CORM-A1 by 13%, 
further supporting the key role of NAD+ depletion in 
antiplatelet effects of CORM-A1.
DISCUSSION
Platelet aggregation is an energy-demanding pro-
cess,15,16 and recent evidence suggest a high substrate 
plasticity of metabolism in platelets.17,19,42,43 In the present 
work, to our knowledge for the first time, we provide evi-
dence that CO affords antiplatelet effects by simultane-
ous and efficient inhibition of 2 major ATP–generating 
pathways: mitochondrial respiration, attributed to the inhi-
bition of cytochrome c oxidase, and glycolysis, ascribed 
to cytosolic NAD+ depletion. Interestingly, an inhibition 
of glycolysis or mitochondrial respiration individually, 
using classical metabolic inhibitors, did not inhibit plate-
let aggregation because these 2 pathways compensate 
each other, as also suggested previously.19 Combined 
inhibition of glycolysis and mitochondrial respiration with 
oligomycin and 2DG, respectively, afforded pronounced 
platelet inhibition. In this context, our results showing that 
CORM-A1–induced a simultaneous inhibition of glycoly-
sis and mitochondrial respiration underscores the ability 
of CO released from CORM-A1 to overcome metabolic 
plasticity of platelets. CORM-A1–derived CO effectively 
inhibits platelet aggregation by compromising at the 
same time 2 major pathways of platelet bioenergetics 
by distinct mechanisms culminating in NAD+ and ATP 
depletion. Given the fact that the sGC is a target for CO 
gas in platelets,9 but not for CORM-A111,12 we suspect 
that bioenergetic effects of CORM-A1 may not neces-
sarily be shared by gaseous CO.
The effects of CO on mitochondrial respiration and 
glycolysis, although clearly observed for resting plate-
lets, were more pronounced in platelets metabolically 
activated by thrombin, oligomycin (activating platelet gly-
colysis; Figure 3A and 3B), or FCCP (activating maxi-
mal mitochondrial respiration; Figure 1C). Platelets in the 
settings of prothrombotic activation increase energetic 
demands15,16,19 and, apparently in such settings, platelets 
also became more susceptible to the inhibitory effects of 
CO. Altogether, the concentration-dependent inhibition 
of platelet aggregation by CORM-A1 was accompanied 
by the concentration-dependent inhibition of platelet bio-
energetics; both ensued in the same range of CORM-A1 
concentrations and pertained to 2 major pathways of ATP 
generation, overcoming substrate plasticity of platelets.
Indeed, metabolic plasticity enables platelet aggrega-
tion even after inhibition of a single metabolic pathway,16,19 
because platelets use diverse metabolic fuels—not only 
glucose, free fatty acids and glutamine, but also gly-
cogen, citrate (added to the blood during collection), 
albumin, and acetate.17,19,42,44 Recently, Ravi et al19 dem-
onstrated that the activation of platelets with thrombin 
results in metabolic reprogramming, leading to increased 
aerobic glycolysis, fatty acid oxidation and glutaminolysis, 
which all compensate each other. We confirmed platelet 
metabolic plasticity in our experimental set-up (Figure 3), 
demonstrating that selective inhibition of mitochondrial 
respiration (by oligomycin, antimycin A, rotenone) did 
not or only slightly (less than by 10%) inhibited platelet 
aggregation. Single inhibitors of mitochondrial respiration 
were almost ineffective in inhibition of platelet aggrega-
tion (Figure 3C), but inhibition of mitochondrial respira-
tion was compensated by an almost 3-fold increase in 
glycolysis (Figure 3A and 3B), which probably met plate-
let aggregation energy requirements. In turn, glycolysis 
inhibition by 100 mmol/L 2DG slightly (by 21%) inhib-
ited platelet aggregation, implying that glycolysis might 
be more important for platelet activity. It was suggested 
that in resting platelets ATP is produced mainly (65%) 
in glycolysis and only 35% in oxidative phosphoryla-
tion.18 Clearly, upon platelet activation, the contributions 
of these metabolic pathways may be different, depend-
ing on the substrates’ availability, underscoring platelets’ 
plasticity. Interestingly, 3PO is known as an inhibitor of 
glycolysis,45 but recently it was demonstrated to target 
and inhibit also TCA cycle and mitochondrial respiratory 
chain.46 In our model, 3PO appeared to inhibit not only 
glycolysis, but also oxygen consumption (Figure 3A and 
3B), resulting in the inhibition of platelet aggregation 
in contrast to other metabolic inhibitors given individu-
ally. Combined inhibition of both glycolysis and oxidative 
phosphorylation with 2DG and oligomycin (Figure 3D 
and 3E) resulted in almost complete inhibition of metab-
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aggregation. Given extraordinary platelet metabolic plas-
ticity, high efficacy of CO released from CORM-A1 in the 
inhibition of platelet aggregation rely on the inhibition of 
both oxidative phosphorylation and glycolysis and subse-
quent efficient blocking of ATP production necessary for 
platelet aggregation.
As regards inhibition of oxidative phosphorylation, 
we demonstrated that in resting platelets, CO released 
from CORM-A1 inhibited mitochondrial respiration in 
a concentration-dependent manner. A CORM-A1–in-
duced fall in concentrations of fumarate and malate 
(Figure 4) confirms reduced TCA turnover in the pres-
ence of CO, while the imbalance in NAD+ and NADH 
concentrations, seen as increased NADH/NAD+ ratio, 
confirms the inhibition of oxidative phosphorylation by 
CO. Altogether, metabolomic results, together with the 
profile of CORM-A1–induced effects on OCR, provide 
evidence that CORM-A1 inhibited mitochondrial res-
piration in platelets, most probably by binding to cyto-
chrome c oxidase, which is a well-known target for CO 
action.47 Moreover, CORM-A1–induced falls in fuma-
rate and malate (Figure 4) may also suggest succinate 
dehydrogenase as another possible target for CO in 
mitochondria. However it seems to be of less signifi-
cance for platelets’ mitochondrial respiration, as evi-
denced by the lack of antiplatelet effects of dimethyl 
malonate (Figure 6Q), a cell permeable precursor of 
succinate dehydrogenase inhibitor.48 Surprisingly, 
mitochondria in platelets were more susceptible to the 
inhibitory effects of CO, as compared with microglia30 
or endothelial cells,31 where only higher concentra-
tions of CO inhibited mitochondrial respiration. These 
results suggest an important regulatory role of mito-
chondrial ATP turnover in platelets.
Interestingly, CO modulated platelet glycolysis in 
a biphasic way—activated by lower and inhibited by 
higher concentrations of CORM-A1 (Figure 1). These 
results suggest that the observed activation of glycoly-
sis at lower concentrations of CORM-A1 was a com-
pensatory response to the inhibition of mitochondrial 
respiration. However, CORM-A1 at higher concentra-
tions induced inhibition of mitochondrial respiration 
and glycolysis, the latter possibly, by separate cytosolic 
target for CO. In the presence of CORM-A1, we noted 
a strong increase in proximal metabolites of glycoly-
sis (hexose-6-phosphate, fructose-1,6-bis-phosphate, 
DHAP and GA3P) and PPP, contrary to the metabo-
lites of distal glycolysis (3-phospho-glicerate, phos-
phoenolpyruvate and pyruvate), which were unchanged 
(Figure 5). These results suggest that glycolysis inhi-
bition by CO might be targeted at GAPDH, which con-
tains a haem moiety, and CO–haem interaction may 
inhibit GAPDH.49 However, the activity of GAPDH in 
platelets was not inhibited by CORM-A1 (Figure 5). 
Another reason for the inhibition of GAPDH activ-
ity and subsequent inhibition of glycolysis (Figure 5) 
could be a substantial drop in NAD+ (Figure 4), primar-
ily linked to the inhibition mitochondrial respiration by 
CO, and a subsequent increase in NADH/NAD+ ratio. 
However, due to NAD+ compartmentalization (mito-
chondria contain up to 70% of total NAD content50), 
it is necessary to consider a separate cytosolic NAD+ 
pool involved in glycolysis, which may be regenerated 
from the metabolism of pyruvate by LDH, or through 
the action of glycerol-3-phosphate shuttle or malate-
aspartate shuttle.51 In the present work, we exclude 
the importance of malate-aspartate shuttle in NAD+ 
regeneration in platelets (lack of the effects of ami-
nooxyacetic acid added alone or in combination with 
other compounds on platelet aggregation; data not 
shown), but we demonstrate that the addition of pyru-
vate: (1) induced LDH–dependent regeneration of 
NAD+ accompanying lactate extrusion, (2) reversed 
glycolysis inhibition at the level of GAPDH, and most 
importantly, (3) abrogated antiaggregatory effects of 
CORM-A1 (Figure 6). Indeed, in the presence of pyru-
vate, NADH/NAD+ ratio was normalized, and accumu-
lation of proximal glycolysis and PPP intermediates 
were reversed (Figure 6D through 6F and 6H through 
6K). Furthermore, inhibition of LDH–dependent 
regeneration of NAD+ by GSK2837808A resulted in 
the elimination of the effect of pyruvate (100 µmol/L) 
on CORM-A1–inhibited platelet aggregation. Inhi-
bition of LDH with simultaneous inhibition of oxida-
tive phosphorylation (Figure 6Q) reduced platelet 
aggregation. These results confirmed the key role 
of LDH–dependent NAD+ regeneration for glycolytic 
flux, the inhibition of which together with the inhibition 
of mitochondrial respiration resulted in the inhibition 
of platelet aggregation. Accordingly, NAD+ depletion 
and subsequent inhibition of glycolysis together with 
mitochondrial respiration are 2 major targets for CO–
induced downregulation of platelet bioenergetics. In 
the present work, we indicate the importance of NAD+ 
in platelet glycolysis and aggregation, and suggest 
that CO, apart from inhibiting cytochrome c oxidase in 
mitochondria, has another cytosolic target(s) decreas-
ing availability of NAD+, that was, however, not ulti-
mately identified here.
Generally, among the enzymes involved in NAD+ 
turnover, there are NAD+–regenerating enzymes (as 
LDH, malate-aspartate shuttle, glycerol-3-phosphate 
shuttle), NAD+–salvage enzymes (as NAD+ synthase), 
and NAD+–consuming enzymes (sirtuins, poly [ADP-
ribose] polymerases, cADP-ribose synthases).51 Little 
is known about the NAD+ turnover in platelets, how-
ever, it was shown that platelets contain an enzy-
matic machinery to metabolize nicotinamide riboside 
into NAD.52 We directed our attention towards CD38 
(cADP-ribose synthase), which generates one mol-
ecule of cADP-ribose for every 100 molecules of 
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of cellular NAD+ availability.53 In fact, we found that 1 
µmol/L 78c (inhibitor of CD38) induced a slight, but 
significant reduction of CORM-A1–induced inhibi-
tion of platelet aggregation, supporting the view that 
modulation of availability of NAD+ by CD38 or other 
enzymes of NAD+ turnover may influence antiplate-
let effects of CORM-A1. However, a direct target for 
CO responsible for NAD+–deficiency still needs to be 
identified. It was demonstrated in pancreatic islets that 
CO activates CD38 through the activation of sGC.54 
Nevertheless, in platelets CO released from CORMs 
does not act through sGC (see Refs11,12 and Figure 
IV in the Data Supplement) making CO/cGMP/CD38 
pathway unlikely to operate in platelets.
Previously, the effects of CO on glycolysis were dem-
onstrated among others in endothelial cells, whereby CO 
inhibited glycolysis and activated PPP.31–33 Some authors 
claim that CO-inhibition of glycolysis is attributed to the 
inhibition of CBS (cystathionine-β-synthase), which 
through the reduction of methylation of PFK-1/fructose 
bisphosphatase type-3 (PFKFB3; an activator of glyco-
lytic flux) inhibited glycolysis on the level of PFK-1 and 
redirected glucose towards PPP.55 As shown in Figure 5, 
the concentration of fructose-1,6-phosphate as well as 
the combined concentration of DHAP and GA3P were 
increased in response to CORM-A1, whereas the con-
centrations of 3-P-glycerate, phosphoenolpyruvate and 
pyruvate were unchanged (1,3-bisphosphoglycerate 
was not analyzed). At first glance, the data could exclude 
the involvement of reduced activation of PFKFB3 in 
platelets in response to CO because increased, but not 
decreased concentration of fructose-1,6-phosphate was 
measured. Prolonged 30-minute incubation of plate-
lets with CORM-A1 allowed to observe an inhibition 
of PFK-1 activity, however, not strong enough to avoid 
accumulation of fructose-1,6-bis-phosphate, DHAP 
and GA3P (Figure III in the Data Supplement). These 
data suggest that CBS inhibition, and a consequent 
PFKFB3 demethylation leading to PFK-1 inhibition, was 
not responsible for inhibition of glycolysis in platelets 
treated with CORM-A1, that was in turn ascribed here 
to NAD+ depletion.
Further studies are needed for a detailed explanation 
of biochemical mechanisms of CO action in platelets 
on NAD+ metabolome and elucidation whether haem-
dependent or independent mechanisms are involved. 
Hemoproteins, such as voltage-gated K+ channels56 
and epithelial Na+ channels,57 seem unlikely as targets 
for CO in platelets, as their link with NAD+– consuming 
processes is not obvious. In turn, large-conductance cal-
cium-regulated K+ channel, known to display a relatively 
high affinity to CO, is not abundant in platelets.56
In summary, the results of the present work, to our 
knowledge for the first time, provide evidence that CO 
affords antiaggregatory effects by inhibition of mitochon-
drial respiration and glycolysis, attributed to the inhibition 
of cytochrome c oxidase and depletion of cytosolic NAD+, 
respectively. The results of our study not only uncover 
platelet-specific action of CO on bioenergetics, but also 
point out that metabolism-targeted antiplatelet therapeu-
tic strategies may prove useful for inhibiting excessive 
platelet activation in various diseases.
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